

Table S1 Summary of RRs of treatment-related AEs in clinical trials excluding a trial using ipilimumab

Treatment-related AEs	Number of studies	Effect estimate		Heterogeneity	
		RR (95% CI)	P value	P value	I ² (%)
Any treatment-related AEs	8	1.03 (0.99–1.06)	0.1280	<0.0001	83.2
Treatment-related AEs ≥ grade 3	9	1.21 (1.10–1.32)	<0.0001	0.0006	70.8
Treatment discontinuation due to treatment-related AEs	8	1.71 (1.38–2.12)	<0.0001	0.0063	64.5
Deaths due to treatment-related AEs	9	1.58 (1.06–2.35)	0.0243	0.9100	0.0

RR, relative risk; AEs, adverse events; CI, confidence interval.

Table S2 Summary of RRs of the details of treatment-related AEs in clinical trials excluding a trial using ipilimumab

Treatment-related AEs	Number of studies	Effect estimate		Heterogeneity	
		RR (95% CI)	P value	P value	I ² (%)
Representative clinical symptoms (all-grade)					
Fatigue	7	1.05 (0.95–1.17)	0.3358	0.1024	43.3
Vomiting	6	1.22 (1.04–1.44)	0.0158	0.3262	13.8
Nausea	7	1.07 (0.98–1.16)	0.1181	0.4088	2.1
Diarrhea	7	1.31 (1.14–1.50)	<0.0001	0.3649	8.3
Constipation	7	1.20 (1.05–1.38)	0.0066	0.6835	0.0
Representative hematological toxicities (all-grade)					
Anemia	7	0.99 (0.89–1.11)	0.8958	0.0406	54.4
Neutropenia	6	1.12 (1.01–1.23)	0.0297	0.2870	19.4
Thrombocytopenia	4	1.13 (0.98–1.30)	0.0982	0.3954	0.0
Representative clinical symptoms (≥ grade 3)					
Fatigue	6	1.53 (1.08–2.17)	0.0162	0.2646	22.5
Vomiting	5	0.96 (0.53–1.73)	0.8831	0.4010	0.9
Nausea	6	1.40 (0.85–2.31)	0.1907	0.7153	0.0
Diarrhea	6	1.42 (0.95–2.13)	0.0904	0.9315	0.0
Constipation	6	0.82 (0.32–2.11)	0.6751	0.7400	0.0
Representative hematological toxicities (≥ grade 3)					
Anemia	6	1.10 (0.88–1.37)	0.3906	0.0643	52.0
Neutropenia	6	1.12 (0.98–1.28)	0.0961	0.3473	10.7
Thrombocytopenia	4	1.24 (0.94–1.64)	0.1307	0.9132	0.0

RR, relative risk; AEs, adverse events; CI, confidence interval.




Figure S1 Funnel plots for AEs in clinical trials, including a trial using ipilimumab. Funnel plots for (A) any treatment-related AEs, (B) treatment-related AEs \geq grade 3, (C) treatment discontinuation due to treatment-related AEs, and (D) death due to treatment-related AEs in clinical trials, including a trial using ipilimumab. SE, standard error; RR, relative risks; AEs, adverse events.




Figure S2 Funnel plots for AEs in clinical trials, excluding a trial using ipilimumab. Funnel plots for (A) any treatment-related AEs, (B) treatment-related AEs \geq grade 3, (C) treatment discontinuation due to treatment-related AEs, and (D) death due to treatment-related AEs in clinical trials, excluding a trial using ipilimumab. SE, standard error; RR, relative risks; AEs, adverse events.